We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ViiV Healthcare has submitted applications seeking approval from US and European regulators for a 5mg dispersible-tablet (DT) formulation of its dolutegravir (DTG) drug to treat children with ...